{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T00:57:29Z","timestamp":1791593849869,"version":"4.3.4"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"18","license":[{"start":{"date-parts":[[2013,11,19]],"date-time":"2013-11-19T00:00:00Z","timestamp":1384819200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1007\/s40265-013-0147-7","type":"journal-article","created":{"date-parts":[[2013,11,19]],"date-time":"2013-11-19T01:19:18Z","timestamp":1384823958000},"page":"2053-2066","source":"Crossref","is-referenced-by-count":56,"title":["Eculizumab: A Review of Its Use in Atypical Haemolytic Uraemic Syndrome"],"prefix":"10.1007","volume":"73","author":[{"given":"Gillian M.","family":"Keating","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,11,19]]},"reference":[{"issue":"3","key":"147_CR1","first-page":"121","volume":"70","author":"D Westra","year":"2012","unstructured":"Westra D, Wetzels JFM, Volokhina EB, et al. A new era in the diagnosis and treatment of atypical haemolytic uraemic syndrome. Neth J Med. 2012;70(3):121\u20139.","journal-title":"Neth J Med"},{"issue":"1","key":"147_CR2","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/j.1365-2141.2009.07916.x","volume":"148","author":"CM Taylor","year":"2010","unstructured":"Taylor CM, Machin S, Wigmore SJ, et al. Clinical practice guidelines for the management of atypical haemolytic uraemic syndrome in the United Kingdom. Br J Haematol. 2010;148(1):37\u201347.","journal-title":"Br J Haematol"},{"issue":"4","key":"147_CR3","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1007\/s00467-008-0964-1","volume":"24","author":"G Ariceta","year":"2009","unstructured":"Ariceta G, Besbas N, Johnson S, et al. Guideline for the investigation and initial therapy of diarrhea-negative hemolytic uremic syndrome. Pediatr Nephrol. 2009;24(4):687\u201396.","journal-title":"Pediatr Nephrol"},{"key":"147_CR4","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/1750-1172-6-60","volume":"6","author":"C Loirat","year":"2011","unstructured":"Loirat C, Fremeaux-Bacchi V. Atypical hemolytic uremic syndrome. Orphanet J Rare Dis. 2011;6:60.","journal-title":"Orphanet J Rare Dis"},{"issue":"23","key":"147_CR5","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1056\/NEJMoa1208981","volume":"368","author":"CM Legendre","year":"2013","unstructured":"Legendre CM, Licht C, Muus P, et al. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med. 2013;368(23):2169\u201381.","journal-title":"N Engl J Med"},{"issue":"5","key":"147_CR6","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1159\/000337954","volume":"35","author":"KS Hodgkins","year":"2012","unstructured":"Hodgkins KS, Bobrowski AE, Lane JC, et al. Clinical grand rounds: atypical hemolytic uremic syndrome. Am J Nephrol. 2012;35(5):394\u2013400.","journal-title":"Am J Nephrol"},{"issue":"1","key":"147_CR7","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s00467-010-1556-4","volume":"26","author":"AM Waters","year":"2011","unstructured":"Waters AM, Licht C. aHUS caused by complement dysregulation: new therapies on the horizon. Pediatr Nephrol. 2011;26(1):41\u201357.","journal-title":"Pediatr Nephrol"},{"issue":"4","key":"147_CR8","doi-asserted-by":"crossref","first-page":"554","DOI":"10.2215\/CJN.04760512","volume":"8","author":"V Fremeaux-Bacchi","year":"2013","unstructured":"Fremeaux-Bacchi V, Fakhouri F, Garnier A, et al. Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults. Clin J Am Soc Nephrol. 2013;8(4):554\u201362.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"Suppl. 1","key":"147_CR9","first-page":"195","volume":"97","author":"C Langman","year":"2012","unstructured":"Langman C. Systemic multi-organ complications in atypical hemolytic uremic syndrome (aHUS): retrospective study in a medical practice setting [abstract no. 0490]. Haematologica. 2012;97(Suppl. 1):195\u20136.","journal-title":"Haematologica"},{"issue":"17","key":"147_CR10","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1056\/NEJMra0902814","volume":"361","author":"M Noris","year":"2009","unstructured":"Noris M, Remuzzi G. Atypical hemolytic-uremic syndrome. N Engl J Med. 2009;361(17):1676\u201387.","journal-title":"N Engl J Med"},{"issue":"11","key":"147_CR11","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1038\/nrneph.2012.214","volume":"8","author":"J Zuber","year":"2012","unstructured":"Zuber J, Fakhouri F, Roumenina LT, et al. Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies. Nat Rev Nephrol. 2012;8(11):643\u201357.","journal-title":"Nat Rev Nephrol"},{"issue":"2","key":"147_CR12","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1053\/j.ajkd.2012.07.028","volume":"61","author":"J Schmidtko","year":"2013","unstructured":"Schmidtko J, Peine S, El-Housseini Y, et al. Treatment of atypical hemolytic uremic syndrome and thrombotic microangiopathies: a focus on eculizumab. Am J Kidney Dis. 2013;61(2):289\u201399.","journal-title":"Am J Kidney Dis"},{"key":"147_CR13","unstructured":"European Medicines Agency. Soliris (eculizumab): EU summary of product characteristics. 2011. http:\/\/www.emea.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000791\/WC500054208.pdf . Accessed 8 Oct 2013."},{"key":"147_CR14","unstructured":"Alexion Pharmaceuticals Inc. Soliris\u00ae (eculizumab): US prescribing information. 2012. http:\/\/soliris.net\/sites\/default\/files\/assets\/soliris_pi.pdf . Accessed 8 Oct 2013."},{"key":"147_CR15","unstructured":"Alexion. Alexion\u2019s Soliris (eculizumab) receives marketing approval in Japan for all patients with aHUS [media release]. 2013. http:\/\/news.alexionpharma.com\/press-release\/product-news\/alexions-soliris-eculizumab-receives-marketing-approval-japan-all-patient . Accessed 25 Oct 2013."},{"key":"147_CR16","unstructured":"Alexion Pharma Canada Corp. Alexion\u2019s Soliris (eculizumab) received marketing approval in Canada for patients with atypical HUS [media release]. 2013. http:\/\/www.alexionpharm.com . Accessed 25 Oct 2013."},{"issue":"17","key":"147_CR17","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.2165\/11208300-000000000-00000","volume":"71","author":"K McKeage","year":"2011","unstructured":"McKeage K. Eculizumab: a review of its use in paroxysmal nocturnal haemoglobinuria. Drugs. 2011;71(17):2327\u201345.","journal-title":"Drugs"},{"key":"147_CR18","doi-asserted-by":"crossref","first-page":"5","DOI":"10.2147\/CPAA.S17904","volume":"3","author":"M Ohanian","year":"2011","unstructured":"Ohanian M, Cable C, Halka K. Eculizumab safely reverses neurologic impairment and eliminates need for dialysis in severe atypical hemolytic uremic syndrome. Clin Pharmacol Adv Appl. 2011;3:5\u201312.","journal-title":"Clin Pharmacol Adv Appl"},{"issue":"5","key":"147_CR19","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1056\/NEJMc0808527","volume":"360","author":"J N\u00fcrnberger","year":"2009","unstructured":"N\u00fcrnberger J, Philipp T, Witzke O, et al. Eculizumab for atypical hemolytic-uremic syndrome. N Engl J Med. 2009;360(5):542\u20134.","journal-title":"N Engl J Med"},{"key":"147_CR20","doi-asserted-by":"crossref","unstructured":"Fern\u00e1ndez-de Larrea C, Cofan F, Oppenheimer F, et al. Efficacy of eculizumab in the treatment of recurrent atypical hemolytic-uremic syndrome after renal transplantation. Transplantation. 2010;89(7):903\u20134.","DOI":"10.1097\/TP.0b013e3181ccd80d"},{"key":"147_CR21","doi-asserted-by":"crossref","first-page":"2644","DOI":"10.1111\/j.1600-6143.2009.02817.x","volume":"9","author":"V Chatelet","year":"2009","unstructured":"Chatelet V, Fremeaux-Bacchi V, Lobbedez T. Safety and long-term efficacy of eculizumab in a renal transplant patient with recurrent atypical hemolytic-uremic syndrome. Am J Transplant. 2009;9:2644\u20135.","journal-title":"Am J Transplant"},{"key":"147_CR22","first-page":"45","volume":"3","author":"M Ohanian","year":"2011","unstructured":"Ohanian M, Cable C, Halka K. Reduced dose maintenance eculizumab in atypical hemolytic uremic syndrome (aHUS): an update on a previous case report. Clin Pharmacol. 2011;3:45\u201350.","journal-title":"Clin Pharmacol"},{"key":"147_CR23","doi-asserted-by":"crossref","unstructured":"Legault DJ, Boelkins MR. Successful treatment of aHUS recurrence and arrest of plasma exchange resistant TMA post-renal transplantation with the terminal complement inhibitor eculizumab [abstract no. 2421]. Blood. 2009;114(22 Suppl).","DOI":"10.1182\/blood.V114.22.2421.2421"},{"issue":"12","key":"147_CR24","doi-asserted-by":"crossref","first-page":"3337","DOI":"10.1111\/j.1600-6143.2012.04252.x","volume":"12","author":"J Zuber","year":"2012","unstructured":"Zuber J, Le Quintrec M, Krid S, et al. Eculizumab for atypical hemolytic uremic syndrome recurrence in renal transplantation. Am J Transplant. 2012;12(12):3337\u201354.","journal-title":"Am J Transplant"},{"issue":"12","key":"147_CR25","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1002\/ajh.21862","volume":"85","author":"HC Prescott","year":"2010","unstructured":"Prescott HC, Wu HM, Cataland SR, et al. Eculizumab therapy in an adult with plasma exchange-refractory atypical hemolytic uremic syndrome. Am J Hematol. 2010;85(12):976\u20137.","journal-title":"Am J Hematol"},{"key":"147_CR26","author":"H Povey","year":"2013","unstructured":"Povey H, Vundru R, Junglee N, et al. Renal recovery with eculizumab in atypical hemolytic uremic syndrome following prolonged dialysis. Clin Nephrol. 2013;. doi: 10.5414\/CN107958 .","journal-title":"Clin Nephrol"},{"issue":"Suppl 3","key":"147_CR27","first-page":"37","volume":"24","author":"K Gras","year":"2011","unstructured":"Gras K, Koch M, Nashan B, et al. Eculizumab improves atypical HUS in a patient after kidney transplantation [abstract]. Transpl Int. 2011;24(Suppl 3):37\u20138.","journal-title":"Transpl Int"},{"issue":"Suppl 3","key":"147_CR28","first-page":"35","volume":"24","author":"N Heyne","year":"2011","unstructured":"Heyne N, Weitz M, Guthoff M, et al. Terminal complement blockade by eculizumab effectively reverses recurrent atypical hemolytic uremic syndrome after kidney transplantation [abstract]. Transpl Int. 2011;24(Suppl 3):35.","journal-title":"Transpl Int"},{"issue":"12","key":"147_CR29","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.1007\/s00467-012-2276-8","volume":"27","author":"R Vilalta","year":"2012","unstructured":"Vilalta R, Lara E, Madrid A, et al. Long-term eculizumab improves clinical outcomes in atypical hemolytic uremic syndrome. Pediatr Nephrol. 2012;27(12):2323\u20136.","journal-title":"Pediatr Nephrol"},{"issue":"4","key":"147_CR30","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1007\/s00467-010-1708-6","volume":"26","author":"SI Al-Akash","year":"2011","unstructured":"Al-Akash SI, Almond PS, Savell VH Jr, et al. Eculizumab induces long-term remission in recurrent post-transplant HUS associated with C3 gene mutation. Pediatr Nephrol. 2011;26(4):613\u20139.","journal-title":"Pediatr Nephrol"},{"issue":"5","key":"147_CR31","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1056\/NEJMc0809959","volume":"360","author":"RA Gruppo","year":"2009","unstructured":"Gruppo RA, Rother RP. Eculizumab for congenital atypical hemolytic-uremic syndrome. N Engl J Med. 2009;360(5):544\u20136.","journal-title":"N Engl J Med"},{"issue":"Suppl","key":"147_CR32","first-page":"109","volume":"13","author":"TC Jungraithmayr","year":"2009","unstructured":"Jungraithmayr TC, Hofer J, Mark W, et al. Successful renal transplantation in a 10 year old boy with factor h associated atypical hemolytic uremic syndrome (aHUS) with plasmapheresis and eculizumab [abstract]. Pediatr Transplant. 2009;13(Suppl):109.","journal-title":"Pediatr Transplant"},{"issue":"5","key":"147_CR33","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1007\/s00467-013-2416-9","volume":"28","author":"K Gulleroglu","year":"2013","unstructured":"Gulleroglu K, Fidan K, Hancer VS, et al. Neurologic involvement in atypical hemolytic uremic syndrome and successful treatment with eculizumab. Pediatr Nephrol. 2013;28(5):827\u201330.","journal-title":"Pediatr Nephrol"},{"issue":"5","key":"147_CR34","doi-asserted-by":"crossref","first-page":"e1385","DOI":"10.1542\/peds.2011-1685","volume":"130","author":"M Giordano","year":"2012","unstructured":"Giordano M, Castellano G, Messina G, et al. Preservation of renal function in atypical hemolytic uremic syndrome by eculizumab: a case report. Pediatrics. 2012;130(5):e1385\u20138.","journal-title":"Pediatrics"},{"issue":"Suppl","key":"147_CR35","first-page":"82","volume":"15","author":"MJG Somers","year":"2011","unstructured":"Somers MJG, Rodig NM. Successful treatment of recurrent atypical hemolytic-uremic syndrome with eculizumab after pediatric kidney transplantation [abstract]. Pediatr Transplant. 2011;15(Suppl):82.","journal-title":"Pediatr Transplant"},{"issue":"17\u201318","key":"147_CR36","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/S0161-5890(96)00078-8","volume":"33","author":"TC Thomas","year":"1996","unstructured":"Thomas TC, Rollins SA, Rother RP, et al. Inhibition of complement activity by humanized anti-C5 antibody and single-chain Fv. Mol Immunol. 1996;33(17\u201318):1389\u2013401.","journal-title":"Mol Immunol"},{"issue":"11","key":"147_CR37","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1038\/nbt1344","volume":"25","author":"RP Rother","year":"2007","unstructured":"Rother RP, Rollins SA, Mojcik CF, et al. Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria. Nature Biotechnol. 2007;25(11):1256\u201364.","journal-title":"Nature Biotechnol"},{"key":"147_CR38","doi-asserted-by":"crossref","unstructured":"Goicoechea de Jorge E, Macor P, Paixao-Cavalcante D, et al. The development of atypical hemolytic uremic syndrome depends on complement C5. J Am Soc Nephrol. 2011;22(1):137\u201345.","DOI":"10.1681\/ASN.2010050451"},{"key":"147_CR39","unstructured":"Legendre C, Greenbaum L, Sheerin N, et al. Efficacy of eculizumab in patients with atypical hemolytic uremic syndrome (aHUS) with or without prior renal transplant: an integrated analysis of two prospective phase II trials [poster]. European Renal Association-European Dialysis & Transplant Association 50th Congress, 18\u201321 May 2013, Istanbul."},{"key":"147_CR40","unstructured":"European Medicines Agency. Soliris (eculizimab): EU assessment report. 2011. http:\/\/www.emea.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Assessment_Report_-_Variation\/human\/000791\/WC500119185.pdf . Accessed 8 Oct 2013."},{"key":"147_CR41","unstructured":"Lapeyraque A-L, Simonetti G, Vilalta R, et al. Efficacy and safety of eculizumab treatment for atypical hemolytic uremic syndrome (aHUS) in pediatric patients: outcomes from a retrospective study [abstract no. 095]. Canadian Society of Nephrology Annual Meeting, 25\u201330 Apr 2012, St. John\u2019s (NL)."},{"key":"147_CR42","doi-asserted-by":"crossref","unstructured":"Fakhouri F, Hourmant M, Campistol JM, et al. Eculizumab (ECU) inhibits thrombotic microangiopathy (TMA) and improves renal function in adult atypical hemolytic uremic syndrome (aHUS) patients (pts) [abstract]. Kidney Week 2013, 5\u201310 Nov 2013, Atlanta (GA).","DOI":"10.1182\/blood.V122.21.2179.2179"},{"key":"147_CR43","unstructured":"Greenbaum LA, Fila M, Tsimaratos M, et al. Eculizumab (ECU) inhibits thrombotic microangiopathy (TMA) and improves renal function in pediatric atypical hemolytic uremic syndrome (aHUS) patients (pts) [abstract]. Kidney Week 2013, 5\u201310 Nov 2013, Atlanta (GA)."},{"issue":"Suppl 1","key":"147_CR44","first-page":"479","volume":"97","author":"R Vilalta","year":"2012","unstructured":"Vilalta R, Al-Akash SI, Davin J, et al. Eculizumab therapy for pediatric patients with atypical hemolytic uremic syndrome: efficacy and safety outcomes of a retrospective study [abstract no. 1155]. Haematologica. 2012;97(Suppl 1):479.","journal-title":"Haematologica"},{"issue":"Suppl","key":"147_CR45","first-page":"52","volume":"15","author":"J-C Davin","year":"2011","unstructured":"Davin J-C, Groothoff JW, Bemelman FJ, et al. Maintenance of renal function under eculizumab despite discontinuation of plasma exchange after a third transplantation for atypical hemolytic uremic syndrome associated with a CFH mutation [abstract]. Pediatr Transplant. 2011;15(Suppl):52.","journal-title":"Pediatr Transplant"},{"issue":"8","key":"147_CR46","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1038\/eye.2013.111","volume":"27","author":"R David","year":"2013","unstructured":"David R, Hochberg-Klein S, Amer R. Resolution of ocular involvement with systemic eculizumab therapy in atypical hemolytic-uremic syndrome. Eye (Lond). 2013;27(8):997\u20138.","journal-title":"Eye (Lond)"},{"issue":"7","key":"147_CR47","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1007\/s00467-012-2130-z","volume":"27","author":"EM Dorresteijn","year":"2012","unstructured":"Dorresteijn EM, van de Kar NC, Cransberg K. Eculizumab as rescue therapy for atypical hemolytic uremic syndrome with normal platelet count. Pediatr Nephrol. 2012;27(7):1193\u20135.","journal-title":"Pediatr Nephrol"},{"key":"147_CR48","doi-asserted-by":"crossref","unstructured":"Greenbaum L, Legendre CM, Babu S, et al. Eculizumab (ECU) in atypical hemolytic uremic syndrome (aHUS) patients with progressing thrombotic microangiopathy (TMA): 2-year data [abstract no. 2084]. Blood. 2012;120.","DOI":"10.1182\/blood.V120.21.2084.2084"},{"key":"147_CR49","unstructured":"Legendre C, Babu S, Cohen D, et al. Efficacy of eculizumab in atypical hemolytic uremic syndrome (aHUS) patients with or without dialysis at baseline [poster]. European Renal Association-European Dialysis & Transplant Association 50th Congress, 18\u201321 May 2013, Istanbul."},{"key":"147_CR50","doi-asserted-by":"crossref","unstructured":"Licht C, Muus P, Legendre CM, et al. Eculizumab (ECU) safety and efficacy in atypical hemolytic uremic syndrome (aHUS) patients with long disease duration and chronic kidney disease (CKD): 2-year results [abstract no. 985]. Blood. 2012;120.","DOI":"10.1182\/blood.V120.21.985.985"},{"key":"147_CR51","unstructured":"Licht C, Muus P, Legendre C, et al. Eculizumab in aHUS patients with a long disease duration and chronic kidney disease: 2-year follow-up [poster]. World Congress of Nephrology, 31 May\u20134 Jun 2013, Hong Kong."},{"key":"147_CR52","doi-asserted-by":"crossref","unstructured":"Ardissino G, Wally Ossola M, Maria Baffero G, et al. Eculizumab for atypical hemolytic uremic syndrome in pregnancy. Obstet Gynecol. 2013;122(2 Pt 2):487\u20139.","DOI":"10.1097\/AOG.0b013e31828e2612"},{"issue":"3","key":"147_CR53","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1111\/j.1365-2141.2010.08099.x","volume":"149","author":"R Kelly","year":"2010","unstructured":"Kelly R, Arnold L, Richards S, et al. The management of pregnancy in paroxysmal nocturnal haemoglobinuria on long term eculizumab. Br J Haematol. 2010;149(3):446\u201350.","journal-title":"Br J Haematol"},{"key":"147_CR54","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1182\/asheducation.V2012.1.617.3798924","volume":"2012","author":"CM Nester","year":"2012","unstructured":"Nester CM, Thomas CP. Atypical hemolytic uremic syndrome: what is it, how is it diagnosed, and how is it treated? Hematology Am Soc Hematol Educ Program. 2012;2012:617\u201325.","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"6","key":"147_CR55","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.ejim.2013.05.008","volume":"24","author":"F Fakhouri","year":"2013","unstructured":"Fakhouri F, Fremeaux-Bacchi V, Loirat C. Atypical hemolytic uremic syndrome: from the rediscovery of complement to targeted therapy. Eur J Intern Med. 2013;24(6):492\u20135.","journal-title":"Eur J Intern Med"},{"key":"147_CR56","unstructured":"Alexion Pharmaceuticals. aHUS observational long term follow-up (LTFU) [ClinicalTrials.gov identifier NCT01522170] US National Institutes of Health. Clinical Trials.gov. 2013. http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01522170 . Accessed 8 Oct 2013."},{"key":"147_CR57","unstructured":"Riedl M, Hofer J, Rosales A, et al. Successful renal transplantation in a child with factor H associated atypical hemolytic uremic syndrome (aHUS) with prophylactic eculizumab treatment [abstract no. 510]. 15th Congress of the International Pediatric Nephrology Association, 29 Aug\u20132 Sep 2010, New York (NY)."},{"issue":"10","key":"147_CR58","doi-asserted-by":"crossref","first-page":"3037","DOI":"10.1016\/j.transproceed.2012.07.141","volume":"44","author":"L Xie","year":"2012","unstructured":"Xie L, Nester CM, Reed AI, et al. Tailored eculizumab therapy in the management of complement factor H-mediated atypical hemolytic uremic syndrome in an adult kidney transplant recipient: a case report. Transplant Proc. 2012;44(10):3037\u201340.","journal-title":"Transplant Proc"},{"issue":"7","key":"147_CR59","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1111\/j.1600-6143.2012.04051.x","volume":"12","author":"S Krid","year":"2012","unstructured":"Krid S, Roumenina LT, Beury D, et al. Renal transplantation under prophylactic eculizumab in atypical hemolytic uremic syndrome with CFH\/CFHR1 hybrid protein. Am J Transplant. 2012;12(7):1938\u201344.","journal-title":"Am J Transplant"},{"issue":"6","key":"147_CR60","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.2215\/CJN.10181110","volume":"6","author":"C Nester","year":"2011","unstructured":"Nester C, Stewart Z, Myers D, et al. Pre-emptive eculizumab and plasmapheresis for renal transplant in atypical hemolytic uremic syndrome. Clin J Am Soc Nephrol. 2011;6(6):1488\u201394.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"8","key":"147_CR61","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1007\/s00467-011-1879-9","volume":"26","author":"M Weitz","year":"2011","unstructured":"Weitz M, Amon O, Bassler D, et al. Prophylactic eculizumab prior to kidney transplantation for atypical hemolytic uremic syndrome. Pediatr Nephrol. 2011;26(8):1325\u20139.","journal-title":"Pediatr Nephrol"},{"key":"147_CR62","unstructured":"Alexion Pharmaceuticals. Atypcial hemolytic-uremic syndrome (aHUS) registry [ClinicalTrials.gov identifier NCT01522183] US National Institutes of Health. Clinical Trials.gov. 2013. http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01522183 . Accessed 8 Oct 2013."}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-013-0147-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40265-013-0147-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-013-0147-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,12]],"date-time":"2022-03-12T22:16:34Z","timestamp":1647123394000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40265-013-0147-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11,19]]},"references-count":62,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["147"],"URL":"https:\/\/doi.org\/10.1007\/s40265-013-0147-7","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,11,19]]}}}